MLSC Neuroscience Consortium

The Massachusetts Life Sciences Center (MLSC) runs the Neuroscience Consortium as a state grant program for pre-clinical neuroscience work in Massachusetts. The consortium has been active since 2013, has committed nearly $10 million, and brings together industry support from AbbVie, Biogen, Celgene, GE, Lundbeck, Merck, Novartis, and Sunovion. It funds translational projects anchored in human disease genetics and focused on Alzheimer's disease and other neurodegenerative conditions. Eligible proposals are limited to Massachusetts institutions, and the record points to collaboration with Massachusetts General Hospital's Alzheimer Disease Research Center. More than 40 principal investigators have been supported since launch, which shows the program's emphasis on sustained research depth rather than one-off awards. The program is built for teams that can show a clear disease pathway, a validated target, a relevant model, or a biomarker use case rather than exploratory biology. Applications are submitted through Airtable, and MLSC's current cycle runs from May 18 to August 31, 2026. Companies that want to join the consortium use the program contact rather than a general grant portal.

Each grant below is a distinct funding opportunity with its own eligibility, scope, and deliverables.